NV 52

Drug Profile

NV 52

Alternative Names: NV-07β

Latest Information Update: 12 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novogen
  • Developer Kazia Therapeutics
  • Class Anti-inflammatories; Isoflavones
  • Mechanism of Action Arachidonic acid inhibitors; Nitric oxide inhibitors; Superoxide dismutase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Inflammatory bowel diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammatory-bowel-disease in Australia (PO)
  • 23 Dec 2010 NV 52 is still in phase I development for Inflammatory bowel disorders in Australia
  • 10 Aug 2006 Novogen has initiated enrolment in a phase I trial for Inflammatory bowel disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top